RT Journal Article
SR Electronic
A1 Vinall, Maria
T1 MEASURE 1: Secukinumab an Effective Treatment for Active AS
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 51
SP 18
OP 18
DO 10.1177/155989771451014
UL http://mdc.sagepub.com/content/14/51/18.abstract
AB Secukinumab, a high-affinity fully human monoclonal immunoglobulin G 1K antibody that selectively binds to and inhibits interleukin-17A, improves the signs and symptoms of active ankylosing spondylitis (AS). This article presents the results of the 16-Week Efficacy and 2-Year Long-term Safety and Efficacy of Secukinumab in Patients With Active Ankylosing Spondylitis trial [MEASURE 1; NCT01358175], which evaluated intravenous loading and maintenance dosing of secukinumab.